Research Laboratories, Vaccine and Virus

Research Laboratories

Vaccine

Virus

Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

The Pharma Data

JUNE 26, 2025

CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines for Children program Merck , operating as MSD outside the United States and Canada, has announced a key regulatory milestone for its respiratory syncytial virus (RSV) prevention program.

Vaccine

Vaccine Hospitals Virus Clinical Trials

WHO Scientific Group Publishes Findings on COVID-19’s Origins

The Pharma Data

JUNE 27, 2025

The group, made up of virologists, epidemiologists, public health professionals, and biosafety specialists, has been working for over three years to shed light on one of the most pressing questions in modern global health: how did SARS-CoV-2, the virus responsible for COVID-19, first infect humans?

Laboratories

Laboratories Virus Research Laboratories International

Join 15,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Accelerating Vaccine Development for the Novel Infectious Disease with Pseudoviruses

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. The world has changed due to its impact – and the race to discover a vaccine is crucial for our return to normalcy.

Vaccine

Vaccine Disease Virus Small Molecule

Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. Pfizer Inc. Jansen, Ph.D., who will be retiring from Pfizer.

Vaccine

Vaccine Research Laboratories Doctors

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

The Pharma Data

JANUARY 24, 2021

(NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.

Vaccine

Vaccine Immune Response Virus Production

Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021

The Pharma Data

JANUARY 17, 2021

Outlook The prevalence of COVID-19 across the globe has increased substantially since the trading update provided in November and Genus expects there will continue to be some challenges for our customers and employees for the remainder of our financial year, despite the prospect of better conditions as vaccines are being made available.

Research Laboratories

Research Laboratories Regulations Production Laboratories

Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Study

The Pharma Data

JANUARY 26, 2021

Pre-clinical data showed the antibody can neutralize the virus by binding to an epitope on SARS-CoV-2 shared with SARS-CoV-1. As the virus continues to evolve, we, along with Lilly and GSK, share the view that we should pursue all possibilities to help end the pandemic and maximize the number of lives that can be saved.

Virus

Virus Trials Nurses Research Laboratories

Codon Digest: Injected Gene Editors

Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 Nature Neuroscience. Read You love to see it! Andreano E. Nature Communications.

DNA

DNA RNA Engineering Licensing

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3.

The Pharma Data

SEPTEMBER 1, 2021

MOVe-AHEAD (MK-4482-013) ( NCT04939428 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households. About Molnupiravir.

Laboratories

Laboratories Clinical Trials Virus Trials

Optimizing your ELISA Assays | BMG LABTECH

BMG Labtech

MARCH 11, 2024

1,2 Anton Schuurs and Bauke van Weemen at the research laboratories of NV Organon, Oss, the Netherlands developed a similar technique which was also published in 1971. ELISAs played a pivotal role in the early detection of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).

Vaccine

Vaccine Molecular Biology Laboratories Virus

Raising Welfare for Lab Rodents

Codon

JULY 21, 2024

As the biotechnologist Alex Telford writes , “Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments.” Work towards improving animal welfare is ongoing and certainly not limited to research laboratories.

Research

Research Engineering Disease Science

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Treatment

Treatment Hospitals Long-Term Care Facilities Virus

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment

Treatment FDA Hospitals Long-Term Care Facilities

Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

The Pharma Data

FEBRUARY 12, 2022

Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories. Pseudovirus and authentic virus testing demonstrate that bebtelovimab retains full neutralizing activity against Omicron – currently the predominant variant in the U.S. About BLAZE-4.

Treatment

Treatment Hospitals FDA Clinical Trials

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. have reached record highs. It was identified from a blood sample taken from one of the first U.S.

Hospitals

Hospitals Treatment Trials Long-Term Care Facilities

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

The Pharma Data

MARCH 11, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Hospitals

Hospitals Trials Long-Term Care Facilities Treatment

Regeneron’s Antibody Cocktail Shows Success in Preventing COVID-19 in Phase 3 Study | 2021-01-26

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.

Vaccine

Vaccine Virus Research Laboratories Trials

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. About Merck.

Trials

Trials Clinical Trials International Production

The Quest for Universal Flu Vaccines

Codon

JANUARY 26, 2025

The influenza virus was not isolated until 1933, when an epidemic in London enabled British researchers Wilson Smith, Christopher Andrewes, and Patrick Laidlaw to collect human influenza virus from patients’ throat washings. Receiving the seasonal vaccine reduces the risk of infection by just 40 percent on average.

Vaccine

Vaccine Immune Response Virus Clinical Trials

The Origins of Adjuvants

Codon

APRIL 4, 2025

Either way, young James set out for the doctor’s home to receive the world’s first vaccine. Jenner vaccinating James Phipps in May 1796. That first vaccination occurred on 14 May, 1796 , at a time when smallpox infected about 1.3 Indeed, half of all vaccines used today contain an adjuvant called “alum.”

Immune Response

Immune Response Vaccine Virus Disease

Drug Discovery Digest

Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

WHO Scientific Group Publishes Findings on COVID-19’s Origins

Trending Sources

Accelerating Vaccine Development for the Novel Infectious Disease with Pseudoviruses

Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021

Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Study

Codon Digest: Injected Gene Editors

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3.

Optimizing your ELISA Assays | BMG LABTECH

Raising Welfare for Lab Rodents

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

Regeneron’s Antibody Cocktail Shows Success in Preventing COVID-19 in Phase 3 Study | 2021-01-26

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

The Quest for Universal Flu Vaccines

The Origins of Adjuvants

Stay Connected